Inspire Medical Systems (INSP) shares plummeted 6.06% in pre-market trading on Tuesday, February 11, 2025, after multiple analysts lowered their price targets on the medical device company.
The sell-off was primarily driven by analysts revising down their expectations for the stock's future performance. Truist Securities cut its price target on INSP to $235 from $250, although it maintained a Buy rating. Meanwhile, Wells Fargo also reduced its price target on INSP to $195 from $198.
No other significant news or events were reported that could have triggered the sharp decline in INSP's stock price. The downward revisions in analysts' price targets appear to be the primary reason behind the pre-market plunge, as investors reacted negatively to the lowered expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.